The biotech received the good news it was hoping for from a top national regulator. This concerned RP1, its advanced melanoma drug. Well before market open, Replimune announced that the U.S. Food and ...

It was the subject of a recommendation downgrade from an analyst. Another pundit reiterated his neutral stance on the company. Rama based much of his new take on the company on the latest developments ...

Physics and Python stuff. Most of the videos here are either adapted from class lectures or solving physics problems. I really like to use numerical calculations without all the fancy programming ...

while handling 'get_globals' implies to me that Thonny parses the contents of globals() after every line on the REPL executes for things like tab completion and viewing variables. That large array ...

Despite a sharp drop in the previous session following the FDA rejection of its skin cancer drug RP1, Replimune (NASDAQ:REPL) shares bounced back on Wednesday even as multiple Wall Street analysts ...

The FDA’s decision to reject Replimune’s (NASDAQ:REPL) lead asset RP1 for a type of skin cancer known as melanoma appears to have boosted its rival, Iovance Biotherapeutics (NASDAQ:IOVA), whose lead ...

On June 11, 2025, the Python core team released Python 3.13.5, the fifth maintenance update to the 3.13 line. This release is not about flashy new language features, instead, it addresses some ...

In this tutorial, we will discover how to harness the power of an advanced AI Agent, augmented with both Python execution and result-validation capabilities, to tackle complex computational tasks. By ...

REPLIMUNE GROUP ($REPL) posted quarterly earnings results on Thursday, May 22nd. The company reported earnings of -$0.82 per share, missing estimates of -$0.77 by $0. ...

A young computer scientist and two colleagues show that searches within data structures called hash tables can be much faster than previously deemed possible. Sometime in the fall of 2021, Andrew ...